Eli Lilly and Company

Wall Street's 'Santa Claus Rally' has typically boosted stocks by around 1.3% over the final five trading days of the year, as well as the first two of the next.

The markets end higher Friday, but the political chaos in Washington has stocks posting a losing week.

Big trends could make these stocks winners next year.

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

Stocks shrug off a new Trump tariff threat as the president-elect vows sweeping levies on the biggest U.S. trading partners.

Experts are divided on the long-term costs of one big move.

The S&P 500 is now around 1% lower than the level it traded in the wake of Trump's election win on Nov. 6.

The weight-loss industry may become more accessible to the average American.

Here are the stocks making the biggest market moves.

Eli Lilly's weight loss treatments have powered the company into the top ten list of megacap U.S. stocks.

Another move higher in Treasury bond yields kept Wall Street in the red, with big jobs and earnings ahead as traders close out a challenging October.

Five Mag 7 giants report earnings this Halloween week. And the big jobs report hits on Friday.

Here are the stocks making the biggest market moves midday.

Membership in the blue chip index may be changing again.

Stocks are looking to protect their hard-fought August gains heading into Nvidia's highly anticipated fiscal-second-quarter earnings on Wednesday.

The S&P 500 has climbed 17% year to date.

Here are the stocks making the biggest market moves today.

Wall Street is riding its longest winning streak in nine months.

Here's what may happen next for the pharma giant's stock price.

But might we buy Novo Nordisk on weakness?

Some boats are rising and some are sinking in this market. We'll also look at LLY, GLD, DKNG, and IYR.

Lots of giveback among individual names today. Is this a pause or the start of something else? Today's new idea is BWA, and we'll look at reader questions.

Viking reported great data for its obesity pill, but the stock is down sharply.

Viking shows strong results in very early clinical trials, but earnings numbers look really bony, so let's see if this is an investment or a speculative trade.

Here's why these names could fall further, including an ideal setup for a bearish play.

The Mag 7 no longer have the glow of AI to drive them when the numbers are less than stellar — and the news tonight doesn’t make me less cautious.

Here's the most important thing for investors to do now as high-profile reports and surprises arrive.

Big moves in anticipation of a Republican victory will create a very dangerous 'sell the news' situation next week.

We've got a mixed bag with Alphabet, Snap and Visa moving up as Chipotle, SoFi and others take it on the chin. Let's check the macro, rates and a plan for AMD.

Let's look at fighting in the Middle East and Russia and the uncertain economic numbers as we brace for earnings from Google, Microsoft, Apple and more.

Several big events are on the horizon that will be market movers. And here's the good news about all this news.

Charting Starbucks, Eli Lilly, gold miners, airlines, AT&T, Walmart and more.

Conditions are good for upside into its earnings report in November.

The most notable aspect of the action Monday was the very poor breadth, as negative news contributes to lackluster performance.

Here's why I see this biotech as a potential rising star in the diet-drug game.

Let's examine Tuesday's ugliness, including volume, the put/call ratio, the S&P and QQQs, and whether there was any panic. Plus a look at heavyweights Nvidia, Tesla and Lilly.

I see an opportunity to short the pharmaceutical giant ahead.

There's no way to anticipate how the market will react to Fed comments this week, but I'm hoping for a buyable pullback in this name.

Mark Zuckerberg's AI team unveiled big plans for AI in an email chain

These 10 compact and midsized sport utility vehicles earned CR’s highest marks, and they sell for wallet-friendly prices.

Here’s what could be next in the AI boom.